best study: patient characteristics
DESCRIPTION
BeSt Study: Patient Characteristics. Total Population508 Female67% Male33% Age (years)54 Duration of symptoms (weeks)23 Time diagnosis – inclusion (weeks) 2 DAS 44 4.4 RF-positive65% With erosion72% Sharp/vdHeijde score 4. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: BeSt Study: Patient Characteristics](https://reader036.vdocument.in/reader036/viewer/2022062422/568139a4550346895da141f7/html5/thumbnails/1.jpg)
![Page 2: BeSt Study: Patient Characteristics](https://reader036.vdocument.in/reader036/viewer/2022062422/568139a4550346895da141f7/html5/thumbnails/2.jpg)
![Page 3: BeSt Study: Patient Characteristics](https://reader036.vdocument.in/reader036/viewer/2022062422/568139a4550346895da141f7/html5/thumbnails/3.jpg)
BeSt Study: Patient Characteristics
Total Population 508Female 67%Male 33%Age (years) 54Duration of symptoms (weeks) 23Time diagnosis – inclusion (weeks) 2DAS 44 4.4RF-positive 65%With erosion 72%Sharp/vdHeijde score 4
Adapted from Goekoop-Ruiterman et al. Arthritis Rheum 2005;52(11):3381-90.
![Page 4: BeSt Study: Patient Characteristics](https://reader036.vdocument.in/reader036/viewer/2022062422/568139a4550346895da141f7/html5/thumbnails/4.jpg)
Remission Rates for Patients on Initial Methotrexate/Infliximab Treatment for Early RA
Adapted from: 1. Allaart et al. Clin Exp Rheumatol 2006;24:S77-S82. 2. Van der Kooij et al. ACR 2006, abstract 658. 3. Van der Kooij et al. EULAR 2007, abstract THU0215. 4. Klarenbeek et al. EULAR 2008, abstract THU0162.
![Page 5: BeSt Study: Patient Characteristics](https://reader036.vdocument.in/reader036/viewer/2022062422/568139a4550346895da141f7/html5/thumbnails/5.jpg)
DAS Results for Initial vs. Delayed Treatment with IFX + MTX at 2-year follow-up
Adapted from van der Kooij et al. EULAR 2007, abstract OP0010.
P<0.001
P=0.005
Delayed: Early RA patients started combination IFX + MTX therapy after failing DMARDs
25
56
18
28
15
5
0
20
40
60
80
100
% failed on IFX + MTX
Initial IFX + MTX (n=120)Delayed IFX+ MTX (n=86)
% stopped IFX and still DAS <2.4
% stopped IFX and still DAS <1.6
IFX = infliximab MTX = methotrexate
![Page 6: BeSt Study: Patient Characteristics](https://reader036.vdocument.in/reader036/viewer/2022062422/568139a4550346895da141f7/html5/thumbnails/6.jpg)
CR
P (
mg
/dL
)
Infliximab 3 mg/kg q 8 + MTX (N=10)
MTX alone (N=10)
Comparative Reduction in CRP Levels
Adapted from Quinn et al. Arthritis Rheum 2005;52:27-35.
0
10
20
30
40
50
Weeks
0 2 6 14 22 30 38 46 54 62 78 104
= Infliximab/placebo infusions
0 to 54 weeks CRP AUC (P<0.05)
Infliximab-free period
![Page 7: BeSt Study: Patient Characteristics](https://reader036.vdocument.in/reader036/viewer/2022062422/568139a4550346895da141f7/html5/thumbnails/7.jpg)
BeSt Safety Results
Sequential monotherapy
Step-up
combination
Initial
combination with prednisone
Initial combination
with infliximab
1 adverse event (% of pts) 43% 47% 37% 39%
No. of adverse events 54 57 49 50
Gastrointestinal symptoms 16% 15% 8% 11%
Rash/mild dermal or mucosal events
10% 12% 9% 6%
Infections 4% 7% 8% 8%
Cardiovascular events 2% 2% 6% 2%
No. of serious adverse events 8 9 17 6
Adapted from Goedkoop-Ruiterman et al. Arthritis Rheum 2005;52:3381-90.